BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36234741)

  • 21. Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
    Wu LQ; Ma X; Zhang C; Liu ZP
    Eur J Med Chem; 2020 Jul; 198():112396. PubMed ID: 32464425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
    Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
    J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.
    Hassani M; Cai W; Holley DC; Lineswala JP; Maharjan BR; Ebrahimian GR; Seradj H; Stocksdale MG; Mohammadi F; Marvin CC; Gerdes JM; Beall HD; Behforouz M
    J Med Chem; 2005 Dec; 48(24):7733-49. PubMed ID: 16302813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA Fragmentation, Cell Cycle Arrest, and Docking Study of Novel Bis Spiro-cyclic 2-oxindole of Pyrimido[4,5-b]quinoline-4,6-dione Derivatives Against Breast Carcinoma.
    Mohamed MF; Abdelmoniem AM; Elwahy AHM; Abdelhamid IA
    Curr Cancer Drug Targets; 2018; 18(4):372-381. PubMed ID: 28669339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.
    Belinsky M; Jaiswal AK
    Cancer Metastasis Rev; 1993 Jun; 12(2):103-17. PubMed ID: 8375015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates.
    Fagan V; Bonham S; Carty MP; Saenz-Méndez P; Eriksson LA; Aldabbagh F
    Bioorg Med Chem; 2012 May; 20(10):3223-32. PubMed ID: 22522008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
    Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q
    Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
    Siegel D; Yan C; Ross D
    Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
    Bailey SM; Suggett N; Walton MI; Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase.
    Brunton VG; Steele G; Lewis AD; Workman P
    Cancer Chemother Pharmacol; 1998; 41(5):417-22. PubMed ID: 9523739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
    Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
    Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.
    Sharp SY; Kelland LR; Valenti MR; Brunton LA; Hobbs S; Workman P
    Mol Pharmacol; 2000 Nov; 58(5):1146-55. PubMed ID: 11040064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deoxynyboquinones as NQO1-Activated Cancer Therapeutics.
    Parkinson EI; Hergenrother PJ
    Acc Chem Res; 2015 Oct; 48(10):2715-23. PubMed ID: 26444384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction.
    Tudor G; Alley M; Nelson CM; Huang R; Covell DG; Gutierrez P; Sausville EA
    Anticancer Drugs; 2005 Apr; 16(4):381-91. PubMed ID: 15746574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: a review.
    Gutierrez PL
    Free Radic Biol Med; 2000 Aug; 29(3-4):263-75. PubMed ID: 11035255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development.
    Beall HD; Winski SI
    Front Biosci; 2000 Jul; 5():D639-48. PubMed ID: 10877993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of novel benzo- and tetrahydrobenzo-[h]quinoline derivatives as potential DNA-intercalating antitumor agents.
    Jafari F; Baghayi H; Lavaee P; Hadizadeh F; Soltani F; Moallemzadeh H; Mirzaei S; Aboutorabzadeh SM; Ghodsi R
    Eur J Med Chem; 2019 Feb; 164():292-303. PubMed ID: 30599418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
    Abbas SH; Abd El-Hafeez AA; Shoman ME; Montano MM; Hassan HA
    Bioorg Chem; 2019 Feb; 82():360-377. PubMed ID: 30428415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
    Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
    J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.